Also interesting
Takeda Invests Close to 300 Million Euros in its Plasma-Derived Therapies Production Site in Lessines
The investment encompasses a new production facility and a carbon net-zero emissions warehouse.
GMP certification for Exothera further extends its viral vector manufacturing capacity
Exothera achieves GMP certification and extends its facilities by a further 2,100 m² (22,600 ft²) production bringing the total capacity to 8,600 m² (92,570 ft²) for viral vector development and manufacturing...
UCB invests in a bioproduction plant in Braine-l’Alleud
To support the launch of a new generation of products, UCB, the biopharmaceutical company specialized in neurology and immunology, is investing 300 million euros in the construction of an ultra-modern biological production plant at its site in Braine-l’Alleud...